Two buying at Biomark Diagnostics (C:BUX)

Rashid Bux, a Director, acquired 500,000 Common Shares on an indirect ownership basis for registered holder BUX INVESTMENT LTD at a price of $0.150 through a prospectus or prospectus exempt offering on June 18th, 2019. This represents a $75,000 investment into the company's shares and an account share holdings change of 31.8%.

Guoyu Huang, a Senior Officer, also acquired 500,000 Common Shares on an indirect ownership basis for registered holder GRG CONSULTING LTD at the same price. This represents a $75,000 investment into the company's shares and an account share holdings change of 24.1%.

Biomark Diagnostics is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Biomark Diagnostics Inc. is an analytical, bioanalytical and drug metabolism and pharmacokinetic (DM/PK) contract research organization (CRO) servicing pharmaceutical and biotechnology companies in discovery, preclinical and clinical programs supporting investigational new drug (IND) and new drug application (NDA)-enabling studies. The Company is engaged in the cancer diagnostics using metabolites. The Company's metabolomics-based diagnostic assay allows cancer detection. The assay consists of screening for the acetylated form of a drug (Amantadine) given to patients prior to measurement through liquid chromatography mass spectrometry (LC MS) in body fluids. This acetylation is performed by the enzyme, spermine/spermidine N-acetyl transferase (SSAT). SSAT is observed in various cancers, including lung, breast, prostate, melanoma and gastrointestinal (GI) cancers. The analysis of SSAT messenger ribonucleic acid (mRNA) levels in tissue samples allows determination of cancer type.